SPARC:前列腺特异性膜抗原PET/CT标准化分析与报告共识:一项Delphi分析
共识推荐采用分子影像PSMA表达水平与确定性、PROMISE的miTNM、PRIMARY评分、PSMA体积及SUVmean/SUVmax等框架报告PSMA PET/CT,但PSMA PET/CT定义反应或进展的数据不足。
要点
- 推荐使用PROMISE的miTNM框架报告PSMA PET/CT。
- 推荐采用PRIMARY评分进行前列腺内分期。
- SUVmax应区域报告,而非单一部位报告。
核心结论
- SPARC提供了PSMA PET/CT标准化分析与报告共识,可作为未来报告参考。
研究设计与样本
- 五个国际多学科专家组进行文献回顾并制定91条陈述,用于两轮改良Delphi调查。
- 使用RAND适当性方法进行分析。
主要发现
- 两轮调查间共识度增至93%。
- 专家组认可并采用分子影像PSMA表达水平与确定性、PROMISE的miTNM、PRIMARY评分、PSMA体积、SUVmean和SUVmax等报告框架。
- 对新诊断转移性前列腺癌中PSMA PET/CT与传统影像风险分组的关联存在不确定性。
- 专家组未就基于PSMA PET/CT的临床管理计划改善结局达成一致。
- 专家组共识认为SUVmax应区域报告,而非报告单一部位。
关键数值与推荐
- 共识推荐报告PSMA PET/CT时采用分子影像PSMA表达水平与确定性框架。
- 共识推荐使用PROMISE的miTNM框架报告PSMA PET/CT。
- 共识推荐采用PRIMARY评分进行前列腺内分期。
- 共识推荐报告PSMA体积、SUVmean和SUVmax。
- 共识认为SUVmax应区域报告,而非单一部位报告。
临床怎么用
- 在临床报告中整合SPARC共识推荐的统一PSMA PET报告标准,以改善影像专家与治疗临床医生之间的沟通。
局限性
- 对新诊断转移性前列腺癌中PSMA PET/CT与传统影像风险分组的关联存在不确定性。
- 缺乏基于PSMA PET/CT的临床管理计划改善结局的共识。
- 标准化PSMA PET/CT定义反应或进展的数据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an evolving diagnostic tool for prostate cancer. There is a need to harmonise existing guidelines and reporting recommendations for PSMA PET/CT. The Standardised PSMA PET/CT Analysis and Reporting Consensus (SPARC) project aims to consolidate classifications and recommendations by a multidisciplinary and international group of experts under one cohesive framework, establishing a dynamic and evolving structure for PSMA PET/CT reporting. METHODS: We employed a cross-sectional iterative process to define opinions and evaluate consensus. Thirty expert panel members, representing diverse specialities and geographic areas, were selected. A methods expert led the design, data collection, and analysis. Five groups of international multidisciplinary prostate cancer experts convened for literature review and formulation of statements on standardised reporting, detection, primary staging, biochemical recurrence, and treatment response. The groups compiled 91 statements for a two-round modified Delphi survey. The "RAND appropriateness method" was used for the analysis. KEY FINDINGS AND LIMITATIONS: Consensus increased to 93% between two rounds. The panel endorsed and adopted the following frameworks for reporting of PSMA PET/CT: molecular imaging PSMA for expression level and certainty, miTNM by PROMISE for reporting of PSMA PET/CT, the PRIMARY score for intraprostatic staging, PSMA volume, mean standardised uptake value, and maximum standardised uptake value (SUVmax). There were uncertainty about correlating PSMA PET/CT with conventional imaging risk groups in newly diagnosed metastatic prostate cancer and a lack of agreement that clinical management plans based upon PSMA PET/CT improved outcomes. There was consensus that SUVmax should be reported regionally, rather than reporting a single site. There were insufficient data to standardise a definition of response or progression by PSMA PET/CT. CONCLUSIONS AND CLINICAL IMPLICATIONS: SPARC provides a standardised PSMA PET/CT analysis and reporting consensus to serve as a future reference for PSMA PET/CT reporting. Integration of common PSMA PET reporting criteria under one umbrella improves the explanation of imaging findings between imaging experts and treating clinicians for clinical implementation.
引用
- Herrmann K, Walz J, MacLennan S, et al. SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis. Eur Urol. 2025. PMID: 40945999. doi:10.1016/j.eururo.2025.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。